163 related articles for article (PubMed ID: 21856036)
21. Expression, purification, and characterization of human dipeptidyl peptidase IV/CD26 in Sf9 insect cells.
Dobers J; Zimmermann-Kordmann M; Leddermann M; Schewe T; Reutter W; Fan H
Protein Expr Purif; 2002 Aug; 25(3):527-32. PubMed ID: 12182835
[TBL] [Abstract][Full Text] [Related]
22. Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior.
Tan EY; Mujoomdar M; Blay J
Am J Pathol; 2004 Jul; 165(1):319-30. PubMed ID: 15215186
[TBL] [Abstract][Full Text] [Related]
23. Fab'-induced folding of antigenic N-terminal peptides from intrinsically disordered HIV-1 Tat revealed by X-ray crystallography.
Serrière J; Dugua JM; Bossus M; Verrier B; Haser R; Gouet P; Guillon C
J Mol Biol; 2011 Jan; 405(1):33-42. PubMed ID: 21035463
[TBL] [Abstract][Full Text] [Related]
24. Complex of dipeptidyl peptidase II with adenosine deaminase.
Sharoyan SG; Antonyan AA; Mardanyan SS; Lupidi G; Cuccioloni M; Angeletti M; Cristalli G
Biochemistry (Mosc); 2008 Aug; 73(8):943-9. PubMed ID: 18774942
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 envelope gp120 and viral particles block adenosine deaminase binding to human CD26.
Valenzuela A; Blanco J; Callebaut C; Jacotot E; Lluis C; Hovanessian AG; Franco R
Adv Exp Med Biol; 1997; 421():185-92. PubMed ID: 9330696
[TBL] [Abstract][Full Text] [Related]
26. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation.
Dong RP; Tachibana K; Hegen M; Munakata Y; Cho D; Schlossman SF; Morimoto C
J Immunol; 1997 Dec; 159(12):6070-6. PubMed ID: 9550406
[TBL] [Abstract][Full Text] [Related]
27. The significance of hypersialylation of dipeptidyl peptidase IV (CD26) in the inhibition of its activity by Tat and other cationic peptides. CD26: a subverted adhesion molecule for HIV peptide binding.
Smith RE; Talhouk JW; Brown EE; Edgar SE
AIDS Res Hum Retroviruses; 1998 Jul; 14(10):851-68. PubMed ID: 9671214
[TBL] [Abstract][Full Text] [Related]
28. Cell surface adenosine deaminase binds and stimulates plasminogen activation on 1-LN human prostate cancer cells.
Gonzalez-Gronow M; Hershfield MS; Arredondo-Vega FX; Pizzo SV
J Biol Chem; 2004 May; 279(20):20993-8. PubMed ID: 15016824
[TBL] [Abstract][Full Text] [Related]
29. Effects of nonapeptides derived from the N-terminal structure of human immunodeficiency virus-1 (HIV-1) Tat on suppression of CD26-dependent T cell growth.
Wrenger S; Reinhold D; Faust J; Mrestani-Klaus C; Brandt W; Fengler A; Neubert K; Ansorge S
Adv Exp Med Biol; 2000; 477():161-5. PubMed ID: 10849743
[TBL] [Abstract][Full Text] [Related]
30. Functional characterization of human cyclin T1 N-terminal region for human immunodeficiency virus-1 Tat transcriptional activation.
Asamitsu K; Hibi Y; Imai K; Victoriano AF; Kurimoto E; Kato K; Okamoto T
J Mol Biol; 2011 Jul; 410(5):887-95. PubMed ID: 21763494
[TBL] [Abstract][Full Text] [Related]
31. Clustered charged amino acids of human adenosine deaminase comprise a functional epitope for binding the adenosine deaminase complexing protein CD26/dipeptidyl peptidase IV.
Richard E; Alam SM; Arredondo-Vega FX; Patel DD; Hershfield MS
J Biol Chem; 2002 May; 277(22):19720-6. PubMed ID: 11901152
[TBL] [Abstract][Full Text] [Related]
32. Dipeptidyl peptidase IV (DPPIV/CD26)-based prodrugs of hydroxy-containing drugs.
Diez-Torrubia A; Cabrera S; Lambeir AM; Balzarini J; Camarasa MJ; Velázquez S
ChemMedChem; 2012 Apr; 7(4):618-28. PubMed ID: 22307932
[TBL] [Abstract][Full Text] [Related]
33. The multifunctional or moonlighting protein CD26/DPPIV.
Boonacker E; Van Noorden CJ
Eur J Cell Biol; 2003 Feb; 82(2):53-73. PubMed ID: 12647932
[TBL] [Abstract][Full Text] [Related]
34. Decreased dipeptidyl peptidase IV enzyme activity of plasma soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals.
Hosono O; Homma T; Kobayashi H; Munakata Y; Nojima Y; Iwamoto A; Morimoto C
Clin Immunol; 1999 Jun; 91(3):283-95. PubMed ID: 10370373
[TBL] [Abstract][Full Text] [Related]
35. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
Gupta S; Mitra D
Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
[TBL] [Abstract][Full Text] [Related]
36. Roles of cysteines in rat dipeptidyl peptidase IV/CD26 in processing and proteolytic activity.
Dobers J; Grams S; Reutter W; Fan H
Eur J Biochem; 2000 Aug; 267(16):5093-100. PubMed ID: 10931192
[TBL] [Abstract][Full Text] [Related]
37. The N-terminal X-X-Pro sequence of the HIV-1 Tat protein is important for the inhibition of dipeptidyl peptidase IV (DP IV/CD26) and the suppression of mitogen-induced proliferation of human T cells.
Wrenger S; Reinhold D; Hoffmann T; Kraft M; Frank R; Faust J; Neubert K; Ansorge S
FEBS Lett; 1996 Apr; 383(3):145-9. PubMed ID: 8925885
[TBL] [Abstract][Full Text] [Related]
38. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).
Balzarini J; Andersson E; Schols D; Proost P; Van Damme J; Svennerholm B; Horal P; Vahlne A
Int J Biochem Cell Biol; 2004 Sep; 36(9):1848-59. PubMed ID: 15183349
[TBL] [Abstract][Full Text] [Related]
39. Dipeptidyl peptidase IV in the hypothalamus and hippocampus of monosodium glutamate obese and food-deprived rats.
Alponti RF; Frezzatti R; Barone JM; Alegre Vde S; Silveira PF
Metabolism; 2011 Feb; 60(2):234-42. PubMed ID: 20153005
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of dipeptidyl peptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides.
Durinx C; Lambeir AM; Bosmans E; Falmagne JB; Berghmans R; Haemers A; Scharpé S; De Meester I
Eur J Biochem; 2000 Sep; 267(17):5608-13. PubMed ID: 10951221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
